These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 37228442)
21. Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria. Fu H; Zheng J; Cai J; Zeng K; Yao J; Chen L; Li H; Zhang J; Zhang Y; Zhao H; Yang Y Cell Physiol Biochem; 2018; 47(1):293-301. PubMed ID: 29768257 [TBL] [Abstract][Full Text] [Related]
22. Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy. He D; Du S; He S; Song H; Pu B; Zhang G; Yang C Medicine (Baltimore); 2023 Dec; 102(49):e36554. PubMed ID: 38065887 [TBL] [Abstract][Full Text] [Related]
23. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment. Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843 [TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy. Yang J; Guo X; Wu T; Niu K; Ma X Medicine (Baltimore); 2019 Feb; 98(6):e14420. PubMed ID: 30732196 [TBL] [Abstract][Full Text] [Related]
25. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. Geng Y; Shao Y; Zhu D; Zheng X; Zhou Q; Zhou W; Ni X; Wu C; Jiang J Sci Rep; 2016 Dec; 6():39482. PubMed ID: 28000729 [TBL] [Abstract][Full Text] [Related]
26. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy. Yang J; Xu H; Guo X; Zhang J; Ye X; Yang Y; Ma X Sci Rep; 2018 Feb; 8(1):3044. PubMed ID: 29445100 [TBL] [Abstract][Full Text] [Related]
27. Novel nomograms predicting the survival of patients with nonsurgical thoracic esophageal squamous cell carcinoma treated with IMRT: A retrospective analysis. Du X; Dong J; Yan K; Wang X; Shen W; Zhu S Medicine (Baltimore); 2022 Oct; 101(40):e30305. PubMed ID: 36221349 [TBL] [Abstract][Full Text] [Related]
28. Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy. Tseng RH; Lai KM; Tsai CY; Yan SL Curr Oncol; 2022 Nov; 29(11):8825-8834. PubMed ID: 36421347 [No Abstract] [Full Text] [Related]
29. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer. Yan X; Li G Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568 [TBL] [Abstract][Full Text] [Related]
30. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma. Fu X; Li T; Dai Y; Li J BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297 [TBL] [Abstract][Full Text] [Related]
31. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. Tong YS; Tan J; Zhou XL; Song YQ; Song YJ J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030 [TBL] [Abstract][Full Text] [Related]
32. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600 [TBL] [Abstract][Full Text] [Related]
33. Systemic immune-inflammation index in germ-cell tumours. Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; De Giorgi U; Mego M; Mardiak J Br J Cancer; 2018 Mar; 118(6):831-838. PubMed ID: 29485980 [TBL] [Abstract][Full Text] [Related]
34. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma. Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model. Duan X; Yang B; Zhao C; Tie B; Cao L; Gao Y BMC Cancer; 2023 May; 23(1):432. PubMed ID: 37173662 [TBL] [Abstract][Full Text] [Related]
36. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy. Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292 [TBL] [Abstract][Full Text] [Related]
37. Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma. Koh HK; Park Y; Koo T; Park HJ; Lee MY; Chang AR; Hong S; Bae H In Vivo; 2021; 35(2):1133-1139. PubMed ID: 33622911 [TBL] [Abstract][Full Text] [Related]
38. Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy. Li J; Niu C; Zhang L; Mu Y; Gui X Diagn Interv Radiol; 2024 Sep; 30(5):279-290. PubMed ID: 38836436 [TBL] [Abstract][Full Text] [Related]
39. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Gao Y; Guo W; Cai S; Zhang F; Shao F; Zhang G; Liu T; Tan F; Li N; Xue Q; Gao S; He J J Cancer; 2019; 10(14):3188-3196. PubMed ID: 31289589 [No Abstract] [Full Text] [Related]
40. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. Topkan E; Besen AA; Ozdemir Y; Kucuk A; Mertsoylu H; Pehlivan B; Selek U Mediators Inflamm; 2020; 2020():4392189. PubMed ID: 32565725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]